MADISON, Wis. – Voximetry, a pioneer in advanced dosimetry technology to enable personalized treatments for cancer patients, has finalized a preferred provider agreement with Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radiopharmaceuticals, and commercial-stage antibody-based therapeutic products for the treatment of cancer. Through this agreement, Y-mAbs designates Voximetry as a preferred provider for dosimetry services for radiopharmaceutical clinical trials.
“We are very pleased to be selected by Y-mAbs as a trusted partner, and we are proud to support their innovative pipeline with our tailored dosimetry services,” said Voximetry Chief Executive Officer, Dr. Sue Wallace. “Our ability to help with pre-study design and accurate dose assessments combined with Y-mAbs novel antibody-based therapeutics will enable greater efficiency of the drug development process.”
The agreement, completed in June 2025, designates Voximetry and its advanced Torch® software as a preferred dosimetry vendor for significant or meaningful clinical trial results.
“Our collaboration with the Voximetry team and experience with the results provided by their Torch® software in our Phase 1 GD2-SADA clinical trial, Trial 1001 have demonstrated the importance of advanced dosimetry and responsive services. Effective drug development, especially in pre-targeted radiopharmaceuticals, is accelerated with precision and comprehensive reporting,” said Michael Rossi, Y-mAbs President and Chief Executive Officer. “This preferred vendor relationship will centralize dosimetry services and streamline our work to transform the treatment paradigm for a variety of cancers and improve patients’ lives.”
Y-mAbs currently has two open and ongoing clinical trials utilizing its Pre-Targeted Radioimmunotherapy Technology Platform in the U.S., including the first-in-human, multicenter GD2-SADA Phase 1 clinical trial, Trial 1001, in solid tumors.
About Voximetry
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.